Given the prevalence of AKI associated with OLT and its associated morbidity and mortality, therapeutic studies based on the diagnosis of AKI using a panel of biomarkers including netrin-1, sema3A, IGFBP-1 and TIMP-2 [28] may be possible in the future. This evidence concerns the gene TIMP2 and acute kidney injury.